News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Survival benefits of perioperative durvalumab with neoadjuvant chemotherapy in MIBC – ESMO
ESMO/LinkedIn
Feb 24, 2025, 08:09

Survival benefits of perioperative durvalumab with neoadjuvant chemotherapy in MIBC – ESMO

ESMO (European Society for Medical Oncology) shared a post on LinkedIn:

“Additional analysis from the NIAGARA trial reported survival benefits of perioperative durvalumab with neoadjuvant chemotherapy in both patients with muscle-invasive Bladder Cancer (MIBC) achieving a pathological complete response (pCR) and those not achieving a pCR, as well as a reduction of the risk of developing metastases and cancer-related death.

The novel data provide further support for the use of the immunotherapy-based treatment as a potential new option for cisplatin-eligible patients.

Read about the study results in the ESMO Daily Reporter.”

More posts featuring ESMO.

cancer Durvalumab ESMO ESMO Daily Reporter European Society for Medical Oncology MIBC muscle invasive bladder cancer NIAGARA OncoDaily Oncology
Special Coverage
Blog
Mar 30, 2025, 18:01
Philippe Spiess: Always an honor to deliver an update in the management of bladder cancer with Tom Flaig
Blog
Mar 30, 2025, 17:46
Thought-provoking trial on localized pancreatic cancer presented by Ethan Agritelley at SSO2025 - Duke Surgical Oncology
Blog
Mar 30, 2025, 17:44
Addressing Gaps in Awareness, Care, and Support for the Early-Age Onset Digestive Cancer Community - European Cancer Organisation
Blog
Mar 30, 2025, 17:34
Olga Kantor: Fantastic presentation by Monika Masanam on MIBC after NST at SSO2025
Blog
Mar 30, 2025, 17:19
Carlos Ayala-Navarro on the immune microenvironment in appendiceal cancers - Moffitt Cancer Center
Blog
Mar 30, 2025, 17:19
Roupen Odabashian: Comparing Research Compensation - Healthcare vs AI
Blog
Mar 30, 2025, 17:05
Julien Mazieres: Heterogeneity of resistance mechanisms should lead to a personalized strategy
Blog
Mar 30, 2025, 16:56
Joe Chang: Optimal first-line treatment for EGFR-mutated mNSCLC
Positive
Mar 30, 2025, 16:44
Yüksel Ürün: FDA approves neoadjuvant and adjuvant durvalumab in MIBC
Blog
Mar 30, 2025, 16:43
Highlights from SSO25
Blog
Mar 30, 2025, 16:38
Embracing Palliative Care in Paediatric Oncology from Diagnosis Onwards course is now available on YouTube - SIOPE
Blog
Mar 30, 2025, 16:09
Hedley Lewis: No Family Should Face Childhood Cancer and Life-Threatening Blood Disorders Alone